Ultragenyx has put a price on its newly approved gene therapy for Sanfilippo syndrome type A: $3.95 million. The figure — among the highest ever for a medicine — reopens one of the thorniest debates in modern healthcare: how do we pay for one-time therapies that can transform a life but cost as much as a house or more?
What the money buys
Fayuvi is a one-time gene therapy for a rare, fatal disease that robs young children of the abilities they once had. Unlike a chronic drug taken for years, it is designed to be given once, aiming to halt the disease at its genetic root. That distinction is central to how companies justify the price: a single infusion is meant to replace a lifetime of care for a devastating condition that otherwise has no treatment.
How it compares
Nearly $4 million sounds staggering, and it is — but it sits within an emerging band of ultra-expensive one-time therapies. Recent gene and cell therapies for rare diseases have carried list prices in a similar range: several have landed between roughly $2 million and $4.25 million. Fayuvi is Ultragenyx’s second gene-therapy approval in recent months, part of a wave of treatments targeting single-gene diseases that were, until recently, untreatable.
The economics behind the price
These therapies are expensive to develop and expensive to make, and they treat tiny patient populations — meaning the enormous R&D cost is spread across very few sales. Notably, analysts don’t expect Fayuvi to be a blockbuster; a bigger financial prize for Ultragenyx may be the priority review vouchers that can come with rare-pediatric-disease approvals, which the company can use or sell to bolster its balance sheet. In other words, the business model around ultra-rare therapies is unusual, blending modest direct sales with regulatory incentives.
The payment problem
A multimillion-dollar, one-time cost strains a health-insurance system built around recurring payments. If a patient switches insurers a year later, the plan that paid for the cure never recoups the value of avoided future costs. This has driven interest in novel payment models — outcomes-based agreements (pay only if it works), installment plans spread over years, and specialized reinsurance — though none has fully solved the mismatch. For families, the practical worry is access: even an approved cure means little if coverage is denied or delayed.
Why it matters
The Fayuvi price is a microcosm of a defining tension in medicine: science can increasingly cure rare genetic diseases, but our financing systems weren’t designed for cures that arrive as a single, huge bill. As more of these therapies reach the market, the pressure to rethink how we value and pay for them — fairly to patients, sustainably for the system, and with enough return to keep the science coming — will only grow. Business news, not investment or medical advice.